These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Increased Oral Health-Related Quality of Life Postsynergistic Treatment with Ultrasound and Photobiomodulation Therapy in Patients with Temporomandibular Disorders.
    Author: Panhóca VH, Bagnato VS, Alves N, Paolillo FR, Deana NF.
    Journal: Photobiomodul Photomed Laser Surg; 2019 Nov; 37(11):694-699. PubMed ID: 31589559.
    Abstract:
    Background and objective: The object of this study was to analyze the oral health-related quality of life (OHRQoL) of patients with temporomandibular disorders (TMDs) who were treated simultaneously with ultrasound (US) and photobiomodulation therapy (PBMT). Materials and methods: This study included 13 patients of both genders, with diagnosis of TMD according to the Research Diagnostic Criteria for Temporomandibular Disorders. The patients were treated with equipment consisting of US and PBMT in the same system. The treatment was applied to the left and right sides of the face in the masseter muscle, anterior temporalis muscle, and temporomandibular joint, two sessions per week for a total of eight sessions. The OHRQoL was assessed by the Oral Health Impact Profile (OHIP-14) at three moments: pretreatment (T0), after the eight treatment sessions (T1), and 30 days after termination of treatment (T2). The Wilcoxon, Mann-Whitney U, Kruskall-Wallis, and Spearman's correlation coefficient tests were applied, with a significance threshold of 5%. Results: Psychological discomfort, physical pain, and psychological limitation were the domains where the highest scores were obtained at T0. The total OHIP-14 scores at T1 and T2 were significantly lower than at T0. No statistical differences were observed between T1 and T2. Conclusions: We conclude that synergistic treatment was effective in improving the OHRQoL of patients with TMDs, and that its beneficial effects persisted at 1 month after termination of treatment.
    [Abstract] [Full Text] [Related] [New Search]